Tuesday, 19 Jun 2018

You are here

Drug Costs Vary by 600% in Different Countries

The Canadian Medical Association Journal has studied the costs of prescription drugs in 10 high-income countries (seven European countries, Australia, Canada and New Zealand) and found that many of these medicines varied by more than 600%. (Citation source: http://buff.ly/2sGx1Fn)

They did not include the United Stated because of the high cost of pharmaceutical drugs and the lack of universal health care,  All countries except Canada offered universal coverage of outpatient prescription drugs.

The specifically looked at drugs common to primary care medicine. These primary care drugs included those for hypertension, NSAIDs, opioids, cholesterol-lowering drugs, noninsulin diabetes treatments, gastrointestinal medications and antidepressants.

Analyzing primary care medicines they found the cost range varied by more than 600%. For example, $23 in New Zealand to $171 in Switzerland. The volume of therapies purchased varied by 41%: from 198 days per capita in Norway to 279 days per capita in Germany.

In the 5 countries with universal, single-payer coverage of prescription medications, the average per-person cost was $77. Average costs were $99 in the 4 countries with universal social insurance for prescription drugs and $158 in Canada, which has a mixed system of private and public financing. Higher costs of drugs and the mix of therapies chosen accounted for most of the cost differences between countries.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EULAR 2018 - Day 3 Report

Day 3 highlights include Behcet’s responds to apremilast and that biologics do not differentially affect TKR/THR post-operative infection rates. Be sure to check out today's podcast as well. 

Canada Closer to Marijuana Approval

Reuters reports that Canada’s Senate on Thursday voted to legalize recreational marijuana, clearing a major hurdle that puts the country on track to become the first Group of Seven nation to permit national use of the drug.

Now the law and amendments go to the House of Commons who will need to decide on before the law can be passed.

Advance Practice Clinicians Proliferating in Specialty Practices

An analysis of SK&A outpatient provider files, covering 90% of physician practices in the United States, shows that between 2008 to 2016, there was a 22% increase in the employment of advanced practice clinicians (APCs) by specialty practices.  By 2016, 28% of all specialty practices employed APCs.

Trump Blasts Drug Makers on the Price of Drugs

Reuter's reports Friday that President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans. Nonetheless, many healthcare stocks rose as it became clear the administration had avoided taking aggressive and direct measures to cut drug prices.

Here are many New Sources on this developing story:

Patients May Not Fill Your Prescription

A new study linking administrative claims and electronic health records (EHRs) shows that nearly 40% of patients fill and take newly prescribed methotrexate (MTX), tofacitinib or biologics. 

Kan et al set out to estimate the extent and predictors of primary nonadherence in rheumatoid arthritis (RA) patients who received new prescriptions for methotrexate, biologics or tofacitinib.